NCT00552227View on ClinicalTrials.gov

Isoprostane/FMD Study The Effect of Protein Kinase C (PKC) β Specific Inhibitor LY333531 on Oxidant Stress in Patients With Type 2 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2002

Study Completion Date

July 31, 2005

Conditions

Diabetes Mellitus

Interventions

DRUG

ruboxistaurin

oral 32 mg daily

OTHER

placebo

Trial Locations (1)

Unknown

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9 am to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia

All Listed Sponsors

lead

Chromaderm, Inc.

INDUSTRY

NCT00552227 - Isoprostane/FMD Study The Effect of Protein Kinase C (PKC) β Specific Inhibitor LY333531 on Oxidant Stress in Patients With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter